Intermountain Healthcare names new chief digital officer

Intermountain Healthcare has named Craig Richardville as its new chief digital and information officer. The appointment comes as Intermountain Healthcare, a Utah-based nonprofit system of 33 hospitals and hundreds of clinics and medical groups, completed its merger with SCL Health.

Richardville was also appointed senior vice president of the combined health systems, which goes under the moniker Intermountain Healthcare. In his role, Richardville oversees the system’s information technology, data and digital services, including strategy, operations, applications, cybersecurity and emerging technology.

He previously served as senior vice president, chief information and digital officer at SCL Health. Prior to that, he served as senior vice president and chief information and analytics officer at Atrium Health for more than 20 years.

Intermountain Healthcare and SCL Health completed their merger in April this year, serving patients and communities in Utah, Idaho, Nevada, Colorado, Montana, Wyoming and Kansas. The combined health system employs more than 59,000 caregivers, operates 33 hospitals (including one virtual hospital), runs 385 clinics across seven states and provides health insurance to 1 million people in Utah and Idaho. The combined entity is the 11th largest health system in the U.S. 

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.